What is the role of pegaptanib sodium in the treatment of choroidal neovascularization (CNV)?

Updated: Jul 27, 2020
  • Author: Lihteh Wu, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

Pegaptanib sodium is an aptamer against VEGF165, the isoform identified with pathological angiogenesis. An aptamer is an oligonucleotide that acts like a high affinity antibody to VEGF, neutralizing it before it can contact its receptor.

Pegaptanib sodium is given as an intravitreal injection every 6 weeks.

Overall, pegaptanib sodium was able to decrease visual loss when compared to placebo in a similar fashion to that of PDT therapy with verteporfin. Only 6% of eyes were reported to have an improvement in visual acuity of 3 or more lines after 12 months of follow-up. Unlike therapy with verteporfin, all eyes with exudative ARMD benefited from treatment regardless of lesion composition. In addition, the trials using pegaptanib sodium included eyes with larger lesions than those eyes in the trials using verteporfin. [36]

Complications associated with the intravitreal injection of pegaptanib sodium are few but include retinal detachment and endophthalmitis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!